ABIONYX Pharma SA (EPA:ABNX)

France flag France · Delayed Price · Currency is EUR
2.775
-0.025 (-0.89%)
Jun 3, 2026, 5:35 PM CET
Market Cap98.82M +122.3%
Revenue (ttm)4.06M -10.7%
Net Income-5.55M
EPS-0.16
Shares Out 35.29M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume188,069
Open2.775
Previous Close2.800
Day's Range2.725 - 2.810
52-Week Range1.170 - 5.290
Beta0.58
AnalystsStrong Buy
Price Target10.50 (+278.38%)
Earnings DateSep 24, 2026

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 51
Stock Exchange Euronext Paris
Ticker Symbol ABNX
Full Company Profile

Financial Performance

In 2025, ABIONYX Pharma's revenue was 4.06 million, a decrease of -10.72% compared to the previous year's 4.55 million. Losses were -5.55 million, 26.7% more than in 2024.

Financial Statements